Clinical trials: Intention
Prostate Cancer
Comprehensive Assessment of Cancer Theranostic Response
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study.
- Trial name
- TRAQinform (NCT06815354)
- Testing
- TRAQinform Theranostics
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- AIQ Solutions
COVID-19
Breath Samples Collection Clinical Trial, for Development of the TERA BioStation T101, Intended for CoV-19 Exhalation Products Detection.
The Sponsor has developed a rapid screening tool intended to determine if the subject tested has COVID-19.
- Trial name
- NCT05162495
- Testing
- BioStation T101 and TeraTube
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tera Group
Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
This is a research study intended to further investigate the safety and efficacy of plerixafor in patients with NHL, HD, or MM. Patients who have previously failed stem cell mobilisation attempts or who have previously received…
- Conditions
- Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma, Front Line Mobilization, Transplantation
- Trial name
- PREDICT (NCT00838357)
- Testing
- Generic = Plerixafor
- Where
- 26 sites in France, Germany and 5 more
- Volunteers
- 118 people
- Sponsor
- Genzyme, a Sanofi Company
Non-Hodgkin's Lymphoma, Hodgkin's Disease
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
The purpose of this program is to provide expanded access to plerixafor for patients with NHL, HD, or MM who are to receive treatment with an autologous peripheral stem cell transplant.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- EAP (NCT00720603)
- Testing
- Plerixafor
- Sponsor
- Genzyme, a Sanofi Company
Diabetes Mellitus: Type 1
A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge.
- Trial name
- NCT00662857
- Testing
- Technosphere® Insulin Inhalation Powder, Technosphere Insulin® Inhalation Powder, RAA Population
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mannkind Corporation
Acute Wound, Donor Site
Confirm Performance and Safety of Exufiber When Used as Intended on Donor Sites
This is a single-centre prospective, open, non-comparative, Post-Market Clinical Follow-up (PMCF) investigation to confirm performance and safety of Exufiber® (Gelling fibre dressing) when used as intended on donor sites through…
- Conditions
- Acute Wound, Donor Site, Split Skin Graft
- Trial name
- ExuDS01 (NCT04884568)
- Testing
- Exufiber
- Where
- Sweden
- Volunteers
- 34 people
- Sponsor
- Molnlycke Health Care AB
Prostate Cancer
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for…
- Trial name
- NCT00833248
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 246 people
- Sponsor
- Ferring Pharmaceuticals
End Stage Renal Disease
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
VasQ is an external support implant for arteriovenous fistulas created for dialysis access. This is a postmarket surveillance, prospective, multi-center, randomized, controlled, open label trial enrolling 300 patients randomized…
- Trial name
- NCT06516653
- Testing
- VasQ, Arteriovenous fistula creation for dialysis vascular access
- Where
- 13 sites in United States
- Volunteers
- 300 people
- Sponsor
- Laminate Medical Technologies
Rheumatoid Arthritis
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Study Design \& Objectives: Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with a clinical follow-up between 12 and 14 weeks.
- Trial name
- PRINT (NCT01299545)
- Where
- 37 sites in Canada, France and 6 more
- Volunteers
- 123 people
- Sponsor
- TcLand Expression S.A.
Confirm PCA-9000A PET/CT System is Effective for Its Intended Use
Verification of the Quantitative Accuracy of the PET/CT System Imaging Chain
The purpose of this study will evaluate new technologies that have been included in the new PCA-9000A PET/CT System.
- Trial name
- NCT01701167
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Toshiba America Medical Systems, Inc.
Intubation, Nasogastric
Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage
The purpose of the study i to demonstrate the safety and efficacy of a device that intends to reduce pain/discomfort related to nasogfastric tube usage by reducing the friction between the tube and internal orifice (nose and…
- Trial name
- NCT00781248
- Testing
- NG Shield
- Where
- Israel
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nanovibronix
Anxiety Disorders
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
- Trial name
- NCT00715039
- Testing
- lorazepam, paroxetine
- Where
- 15 sites in United States
- Volunteers
- 169 people
- Sponsor
- Pfizer
Diet Diversity, Infant Nutrition
Infancy to Toddlerhood: Early Nutrition & Tolerance (INTENT)
This is a randomized, controlled, open-label, pragmatic, direct-to-participant trial designed for infants. The study will be conducted using a mobile application platform to engage parents with healthy infants and parents with…
- Trial name
- INTENT (NCT04803981)
- Testing
- SpoonfulONE
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Before Brands, Inc
Diabetic Foot Ulcers (DFUs)
Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care
The main purpose of this research study is to compare the proportion of wound closure in subjects that receive E-GRAFT™ with Standard of Care (SOC) versus FIBRACOL™ with SOC.
- Trial name
- NCT06767501
- Testing
- E-GRAFT ™, FIBRACOL™
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Skye Biologics Holdings, LLC
Inoperable Stage III Non-small Cell Lung Cancer
Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer
The purpose of this study is to evaluate survival in inoperable stage III Non-small Cell Lung Cancer patients following chemo-radiotherapy followed by GV1001 vaccination plus best supportive care.
- Trial name
- LucaVax (NCT01579188)
- Testing
- GV1001, normal saline
- Volunteers
- 600 people
- Sponsor
- Kael-GemVax Co., Ltd.
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Head Lice
NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers
Photoallergic reactions are assumed to be due to a delayed cell-mediated hypersensitivity response that requires the presence of ultraviolet irradiation.
- Trial name
- NCT00605956
- Testing
- NatrOVA Creme Rinse - 1%, NatrOVA Creme Rinse Vehicle Only, Blank Patch
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- ParaPRO LLC
Bioavailability
An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects
The study is an open label, randomized, balanced, two period, two sequence, crossover, single dose, relative bioavailability study in healthy subjects.Each subject, meeting all the inclusion criteria and none of the exclusion…
- Trial name
- NCT06427681
- Testing
- BH006 for injection, Fosaprepitant for injection+Palonosetron hydrochloride injection
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
Cardiac Output Measurements, Healthy Subjects
An Exploratory Clinical Study Non-invasive Monitoring of Cardiac Outputs
Pulsify Medical aims at developing a sensor designed for the non-invasive, continuous and real-time monitoring of cardiac hemodynamics in patients at risk based on new transducer technology and artificial intelligence.
- Trial name
- NCT05734664
- Testing
- Pulsify sensor, State-of-the-art ultrasound equipment
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pulsify Medical
Colorectal Cancer, Colorectal Neoplasms
Longitudinal Performance of Epi proColon
This study will evaluate longitudinal performance of Epi proColon with respect to test positivity, longitudinal adherence to Epi proColon screening, adherence to follow-up colonoscopy and diagnostic yield, as well as assay…
- Trial name
- PERT (NCT03218423)
- Testing
- Epi proColon
- Where
- 6 sites in United States
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc